Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeremie Calais

Showing results (21-30 of 207) with videos related to

Pageof 21
Sort By:
The Journal of Urology|January 27, 2022
Imaging Prostate Cancer: Clinical Utility of Prostate-Specific Membrane AntigenDavid Kuppermann, Jeremie Calais, Leonard S Marks
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 4, 2019
Of Sheep and Wolves: Curtailing Coverage for Essential Imaging Tests Based on Flawed Use and Cost ArgumentsJohannes Czernin, Martin Allen-Auerbach, Jeremie Calais
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 6, 2018
The Utility of PET/CT in the Planning of External Radiation Therapy for Prostate CancerJeremie Calais, Minsong Cao, Nicholas G Nickols
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 5, 2019
The Future of Nuclear Medicine as an Independent SpecialtyJohannes Czernin, Ida Sonni, Aria Razmaria, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 19, 2024
Challenges with <sup>177</sup>Lu-PSMA-617 Radiopharmaceutical Therapy in Clinical PracticeHossein Jadvar, Amir Iravani, Lisa Bodei, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 21, 2018
The influence of PSA flare in mCRPC patients treated with alpha-emitting radiopharmaceuticalsFrancesco Ceci, Giulia Polverari, Jeremie Calais, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 11, 2022
Outcome of Patients with PSMA PET/CT Screen Failure by VISION Criteria and Treated with <sup>177</sup>Lu-PSMA Therapy: A Multicenter Retrospective AnalysisMasatoshi Hotta, Andrei Gafita, Johannes Czernin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 2026
Reply to: Comments on the LUNAR Trial in Oligorecurrent Hormone-Sensitive Prostate CancerLuca F Valle, Jeremie Calais, Amar U Kishan
Annual Review of Medicine|January 29, 2024
Prostate-Specific Membrane Antigen: Gateway to Management of Advanced Prostate CancerLena M Unterrainer, Jeremie Calais, Neil H Bander
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 6, 2025
Reflections on the Demand for PSMA- and SSTR-Targeted Radiopharmaceutical Therapies: Why We Were Wrong (and Why We Will Be Right Eventually)Johannes Czernin, Lisa Bodei, Irvin Modlin, et al.
Pageof 21

Showing results (21-30 of 207) with videos related to

Sort By:
Pageof 21
The Journal of Urology|January 27, 2022
Imaging Prostate Cancer: Clinical Utility of Prostate-Specific Membrane AntigenDavid Kuppermann, Jeremie Calais, Leonard S Marks
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 4, 2019
Of Sheep and Wolves: Curtailing Coverage for Essential Imaging Tests Based on Flawed Use and Cost ArgumentsJohannes Czernin, Martin Allen-Auerbach, Jeremie Calais
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 6, 2018
The Utility of PET/CT in the Planning of External Radiation Therapy for Prostate CancerJeremie Calais, Minsong Cao, Nicholas G Nickols
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 5, 2019
The Future of Nuclear Medicine as an Independent SpecialtyJohannes Czernin, Ida Sonni, Aria Razmaria, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 19, 2024
Challenges with <sup>177</sup>Lu-PSMA-617 Radiopharmaceutical Therapy in Clinical PracticeHossein Jadvar, Amir Iravani, Lisa Bodei, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 21, 2018
The influence of PSA flare in mCRPC patients treated with alpha-emitting radiopharmaceuticalsFrancesco Ceci, Giulia Polverari, Jeremie Calais, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 11, 2022
Outcome of Patients with PSMA PET/CT Screen Failure by VISION Criteria and Treated with <sup>177</sup>Lu-PSMA Therapy: A Multicenter Retrospective AnalysisMasatoshi Hotta, Andrei Gafita, Johannes Czernin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 2026
Reply to: Comments on the LUNAR Trial in Oligorecurrent Hormone-Sensitive Prostate CancerLuca F Valle, Jeremie Calais, Amar U Kishan
Annual Review of Medicine|January 29, 2024
Prostate-Specific Membrane Antigen: Gateway to Management of Advanced Prostate CancerLena M Unterrainer, Jeremie Calais, Neil H Bander
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 6, 2025
Reflections on the Demand for PSMA- and SSTR-Targeted Radiopharmaceutical Therapies: Why We Were Wrong (and Why We Will Be Right Eventually)Johannes Czernin, Lisa Bodei, Irvin Modlin, et al.
Pageof 21